<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789551</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-P00037843</org_study_id>
    <nct_id>NCT04789551</nct_id>
  </id_info>
  <brief_title>T Cell Profiling in Patients With Multiple Sclerosis</brief_title>
  <official_title>T Cell Profiling in Patients With Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this research study is to to learn more about the body's immune response in&#xD;
      patients with multiple sclerosis (MS). In MS, the body's immune cells mistakenly attack an&#xD;
      important part of the nerves of the brain and spinal cord. The immune cells responsible for&#xD;
      attacking the nerves in MS patients is primarily the T cells. A marker was recently&#xD;
      discovered that might specifically identify these damaging T cells from all other T cells in&#xD;
      the body. Understanding which T cells cause the damage in MS patients and understanding more&#xD;
      about these specific T cells may help doctors better understand how MS occurs and could&#xD;
      possibly prevent MS in the future.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>T cell populations</measure>
    <time_frame>up to one week</time_frame>
    <description>compare T cell populations between patients with Multiple Sclerosis and healthy controls</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Multiple Sclerosis Stable Conditions</arm_group_label>
    <description>Multiple sclerosis patients presenting for a routine clinic visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple Sclerosis Acute Flare Up</arm_group_label>
    <description>Multiple sclerosis patients admitted to the hospital with acute symptoms.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
    <description>Patients without any immunological diseases who present for elective surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sample</intervention_name>
    <description>a blood sample will be collected</description>
    <arm_group_label>Control patients</arm_group_label>
    <arm_group_label>Multiple Sclerosis Acute Flare Up</arm_group_label>
    <arm_group_label>Multiple Sclerosis Stable Conditions</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Multiple Sclerosis who present to Boston Children's Hospital will be&#xD;
        enrolled. A group of healthy control patients who present for elective surgery at Boston&#xD;
        Children's Hospital will also be enrolled.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        MS Group Inclusion criteria&#xD;
&#xD;
        -diagnosis of multiple sclerosis and present to the neurology clinic for a regular checkup&#xD;
        or are admitted to the inpatient floor with acute symptoms.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Have an active infection&#xD;
&#xD;
          -  Take T cell modulating drugs&#xD;
&#xD;
        Control Group Inclusion criteria -scheduled for elective surgery&#xD;
&#xD;
          -  without any immunological diseases. Exclusion criteria&#xD;
&#xD;
          -  Have an active infection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lifei Hou, PhD</last_name>
    <phone>617-713-8154</phone>
    <email>lifei.hou@childrens.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston Children's Hopsital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Lifei Hou, PhD</last_name>
      <email>lifei.hou@childrens.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Koichi Yuki, MD</last_name>
      <phone>617-355-6225</phone>
      <email>koichi.yuki@childrens.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 9, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Lifei Hou</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

